Preemptive policy: This is a P&T approved policy and can be used after the drug is FDA approved until it is superseded by an updated policy

CENTENE® Corporation

Clinical Policy: Garetosmab (REGN2477)

Reference Number: CP.PHAR.778
Effective Date: FDA Approval Date
Last Review Date: 05.26
Line of Business: Commercial, HIM/ICHRA, Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Garetosmab (REGN2477) is a monoclonal antibody that inhibits activin A.

FDA Approved Indication(s) [Pending]

REGN2477 is indicated for the treatment of adults with fibrodysplasia ossificans progressiva (FOP).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that REGN2477 is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria*

**Criteria will mirror the clinical information from the prescribing information once FDA-approved*

A. Fibrodysplasia Ossificans Progressiva (must meet all)**:**

1. Diagnosis of FOP;*
2. Prescribed by or in consultation with an orthopedics, orthopedic surgery, rheumatology, endocrinology, or metabolic disease specialist;
3. Age ≥ 18 years;*
4. Presence of *ACVR1* FOP-causing mutation;*
5. Documentation of baseline heterotopic ossification (HO) volume assessed by low-dose whole body computed tomography (WBCT) scan, excluding the head;*
6. Member has a cumulative analog joint involvement scale (CAJIS) score ≤ 19 prior to treatment with REGN2477 (*see Appendix E*);*
7. Failure of both of the following at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated (a and b):^*
   ^For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395
   a. Prednisone used for flare-ups;
   b. Two nonsteroidal anti-inflammatory drugs (NSAIDs) between flare-ups;
8. REGN2477 is not prescribed concurrently with Sohonos™;
9. Dose does not exceed FDA-labeled maximum dose.*

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy*

**Criteria will mirror the clinical information from the prescribing information once FDA-approved*

A. Fibrodysplasia Ossificans Progressiva (must meet all)**:**
1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B)*;
2. Member is responding positively to therapy as evidenced by one of the following (a, b, or c):*
   a. Reduction in flare-ups from baseline;
   b. Improvement in annualized new HO volume as assessed by low-dose WBCT scan;
   c. Increased or stabilized mobility;
3. REGN2477 is not prescribed concurrently with Sohonos;
4. If request is for a dose increase, new dose does not exceed the FDA-labeled maximum dose.*

Approval duration:
Medicaid/HIM/ICHRA – 12 months
Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of

business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or

b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CAJIS: cumulative analog joint involvement scale
FDA: Food and Drug Administration
FOP: fibrodysplasia ossificans progressiva
HO: heterotopic ossification
NSAID: nonsteroidal anti-inflammatory drug
WBCT: whole body computed tomography

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
prednisone	2 mg/kg/day PO	100 mg*
NSAIDs		
ibuprofen	Pediatrics: 4-10 mg/kg PO Q6H Adults: 200-800 mg PO Q6H	Refer to dosing regimen
indomethacin	Pediatrics: 2-4 mg/kg/day PO or 150-200 mg/day (whichever is less), divided TID Adults: 50 mg PO TID	Refer to dosing regimen
celecoxib	Pediatrics and adults: 100-200 mg PO BID	600 mg/day*

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
**Medications and doses recommended per the 2024 The International Clinical Council on FOP Medical Management guidelines*

Appendix C: Contraindications/Boxed Warnings [Pending]

- Contraindication(s): pending

- Boxed warning(s): pending

Appendix D: General Information

- A flare-up is painful soft tissue swelling that may lead to extraskeletal HO
- Flare-up symptoms include, but are not limited to pain, swelling, redness, decreased range of motion, stiffness, and warmth.

Appendix E: CAJIS Score

CAJIS is an assessment of mobility limitation at 15 anatomic locations. Scores are tabulated for each site as normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30. On the basis of FOP features (flare-up activity, body regions affected, thoracic insufficiency syndrome, other complications) and its consequences (impairments in activities of daily living and ambulation, increasing CAJIS), five clinical stages of disease severity have been defined.

CAJIS Score	FOP Clinical Stage
≤ 4	Early
5–18	Moderate
19–24	Severe
≥ 24	Profound
≥ 28	End-of-life

V. Dosage and Administration [Pending]

Indication	Dosing Regimen	Maximum Dose
FOP*	IV; pending	Pending

VI. Product Availability [Pending]

Pending

VII. References

1. ClinicalTrials.gov. A study to assess safety, tolerability and efficacy of garetosmab versus placebo administered intravenously (IV) in adult participants with fibrodysplasia ossificans progressiva (FOP) (OPTIMA). Available at: https://clinicaltrials.gov/study/NCT05394116. Accessed March 30, 2026.
2. Di Rocco M, Forleo-Neto E, Pignolo RJ, et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. *Nat Med*. 2023;29(10):2615-2624.
3. Fibrodysplasia ossificans progressiva. Genetic and Rare Disease (GARD) Information Center; 2026. Available at: https://rarediseases.info.nih.gov/diseases/6445/fibrodysplasia-ossificans-progressiva. Accessed March 30, 2026.
4. Kaplan FS, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2024;3:1-159.

Coding Implications [Pending]

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-

date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
Pending	Pending

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	03.31.26	05.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.